Tranexamic acid (TXA) is legal and widely used as a cosmetic ingredient in the United States. It is not classified as a drug by the FDA in topical cosmetic use, provided claims made about the product do not cross into drug territory — for example, claiming the product treats melasma, a medical condition, would invite FDA scrutiny and potential OTC drug classification.
Transexamic acid is not on the FDA's list of prohibited or restricted cosmetic ingredients (21 CFR Part 700). It is also not restricted under California's Cleaning Product Right to Know Act or Prop 65 at the concentrations used in cosmetics (1–5%). In the EU, TXA is similarly not a restricted cosmetic substance under the EU Cosmetics Regulation (EC) No 1223/2009 Annex II or III, though EU brands must complete a Cosmetic Product Safety Report (CPSR) by a qualified safety assessor before placing the product on market.
Safety profile: TXA is well-characterized pharmacologically (it is a lysine analogue used intravenously to prevent hemorrhage). At topical cosmetic concentrations, it has a strong safety record — it is non-irritating at 1–5%, non-comedogenic, and compatible with most surfactant systems used in cleansers. Patch testing and HRIPT (human repeated insult patch test) data are still recommended before launch as part of your safety substantiation file.
Stability consideration: TXA is water-soluble and relatively stable across a wide pH range (4–8), which makes it well-suited for gel cleansers. However, it should be combined with antioxidants (like vitamin C derivatives) carefully, as some combinations can cause discoloration over time. Accelerated stability testing is non-negotiable — a formula that looks beautiful at batch release may discolor or develop off-odor at month three if not properly validated.
The common mistake founders make is relying solely on a manufacturer's assurance that the formula is stable without requesting independent test data. Always ask for a stability report with real data points (appearance, pH, viscosity, active assay) at T=0, T=4 weeks (50°C), and T=12 weeks (40°C/75% RH) at minimum.
MoCRA (2022) now requires safety substantiation to be on file for all cosmetic products sold in the US. Your safety file for a TXA vitamin C cleanser should include: raw material CoAs and safety data sheets, a formula-level safety assessment, PET results, stability data, and any clinical or consumer use data you have generated.
Ingredients in this answer: Tranexamic Acid
Read the full guide on Private Label Tranexamic Acid Vitamin C Gel Cleanser →